Leerink Partnrs Reduces Earnings Estimates for Kura Oncology

Kura Oncology, Inc. (NASDAQ:KURA) – Analysts at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for Kura Oncology in a report issued on Wednesday, May 14th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of $0.15 per share for the quarter, down from their previous estimate of $0.16. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology’s Q4 2025 earnings at $0.18 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.69) EPS.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million during the quarter, compared to the consensus estimate of $39.08 million.

Several other analysts also recently commented on KURA. UBS Group dropped their price objective on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. Barclays decreased their target price on shares of Kura Oncology from $32.00 to $11.00 and set an “overweight” rating for the company in a research report on Friday, May 2nd. JMP Securities reiterated a “market outperform” rating and set a $28.00 price objective on shares of Kura Oncology in a research note on Tuesday, April 29th. StockNews.com downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Finally, Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $24.50.

Kura Oncology Stock Performance

Kura Oncology stock opened at $6.38 on Monday. Kura Oncology has a 12-month low of $5.41 and a 12-month high of $23.48. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a 50-day simple moving average of $6.37 and a 200 day simple moving average of $8.63. The stock has a market capitalization of $552.35 million, a price-to-earnings ratio of -2.70 and a beta of 0.50.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors have recently made changes to their positions in the company. BVF Inc. IL boosted its stake in shares of Kura Oncology by 202.0% during the first quarter. BVF Inc. IL now owns 7,754,129 shares of the company’s stock valued at $51,177,000 after purchasing an additional 5,186,660 shares during the period. RA Capital Management L.P. purchased a new stake in Kura Oncology in the 4th quarter valued at about $38,769,000. Millennium Management LLC grew its stake in Kura Oncology by 180.1% in the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock worth $20,618,000 after acquiring an additional 1,521,954 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Kura Oncology during the fourth quarter worth approximately $8,518,000. Finally, Marshall Wace LLP purchased a new position in shares of Kura Oncology during the fourth quarter worth approximately $8,265,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.